F-star Therapeutics is a clinical-stage biopharmaceutical company. Co. is engaged in the discovery and development of therapeutics for the treatment of a range of cancers and inflammatory diseases. Co.'s STING (STimulator of INterferon Genes) product portfolio include STING agonist clinical program in oncology, STING antagonist compounds for inflammatory diseases, and STING agonist antibody drug conjugate program for oncology. Co. is developing its SB 11285, as an immunotherapeutic cyclic dinucleotide for the treatment of selected cancers. Co. is also exploring the use of its STING antagonist compounds for the treatment of certain autoimmune and inflammatory diseases. The FSTX average annual return since 2016 is shown above.
The Average Annual Return on the FSTX average annual return since 2016 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether FSTX average annual return since 2016 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the FSTX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|